CN120172884A - 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 - Google Patents

用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 Download PDF

Info

Publication number
CN120172884A
CN120172884A CN202510305793.6A CN202510305793A CN120172884A CN 120172884 A CN120172884 A CN 120172884A CN 202510305793 A CN202510305793 A CN 202510305793A CN 120172884 A CN120172884 A CN 120172884A
Authority
CN
China
Prior art keywords
group
groups
alkyl
substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510305793.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·雷
M·G·庞珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN120172884A publication Critical patent/CN120172884A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202510305793.6A 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 Pending CN120172884A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
US62/311,697 2016-03-22
CN201780031580.2A CN109311827B (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780031580.2A Division CN109311827B (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂

Publications (1)

Publication Number Publication Date
CN120172884A true CN120172884A (zh) 2025-06-20

Family

ID=59899817

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202510305793.6A Pending CN120172884A (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN201780031580.2A Active CN109311827B (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN202210306552.XA Active CN114716387B (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780031580.2A Active CN109311827B (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN202210306552.XA Active CN114716387B (zh) 2016-03-22 2017-03-22 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂

Country Status (27)

Country Link
US (3) US11458213B2 (enExample)
EP (3) EP3433238B1 (enExample)
JP (3) JP7073270B2 (enExample)
KR (4) KR20220063298A (enExample)
CN (3) CN120172884A (enExample)
AU (1) AU2017238181B2 (enExample)
BR (1) BR112018069507A2 (enExample)
CA (1) CA3018709A1 (enExample)
CL (1) CL2018002683A1 (enExample)
CY (1) CY1124487T1 (enExample)
DK (2) DK3925952T3 (enExample)
ES (2) ES2877572T3 (enExample)
FI (1) FI3925952T3 (enExample)
HR (2) HRP20240215T1 (enExample)
HU (2) HUE065327T2 (enExample)
LT (2) LT3925952T (enExample)
MX (1) MX384823B (enExample)
PH (1) PH12018502048A1 (enExample)
PL (2) PL3925952T3 (enExample)
PT (2) PT3925952T (enExample)
RS (2) RS62274B1 (enExample)
RU (2) RU2021115958A (enExample)
SA (1) SA518400103B1 (enExample)
SI (2) SI3925952T1 (enExample)
TR (1) TR201813644T1 (enExample)
WO (1) WO2017165473A1 (enExample)
ZA (1) ZA201806389B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803973B (zh) 2016-08-10 2022-05-24 癌靶技术有限责任公司 螯合psma抑制剂
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
JP2020522506A (ja) * 2017-05-30 2020-07-30 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
EP4008359B1 (en) * 2017-12-11 2024-09-11 Technische Universität München Psma ligands for imaging and endoradiotherapy
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
MX2020006112A (es) * 2017-12-13 2020-08-24 Sciencons AS Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.
IL276528B2 (en) * 2018-02-06 2024-11-01 Univ Johns Hopkins PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy
AU2019219057B2 (en) * 2018-02-06 2022-11-24 Universität Heidelberg FAP inhibitor
MY197419A (en) * 2018-03-30 2023-06-16 Futurechem Co Ltd Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
AU2019287595B2 (en) 2018-04-27 2024-10-31 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
BR112021005931A2 (pt) * 2018-09-28 2021-06-29 Universität Heidelberg composto, complexo e composição farmacêutica
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
EP3993837A1 (en) * 2019-07-02 2022-05-11 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
EP3993838A1 (en) * 2019-07-02 2022-05-11 Novartis AG Prostate specific membrane antigen (psma) ligands and uses thereof
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
IL297323A (en) 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
EP4247798B1 (en) * 2020-11-19 2025-08-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
KR20240022616A (ko) * 2021-06-17 2024-02-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
JP2025506001A (ja) 2022-02-09 2025-03-05 ノバルティス アーゲー ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物
KR20250127126A (ko) * 2022-12-21 2025-08-26 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
JP2012511024A (ja) * 2008-12-05 2012-05-17 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 癌の治療及び撮像用のｃａ−ｉｘ特異性放射性医薬品
CA2755965C (en) * 2009-03-19 2019-04-16 The Johns Hopkins University Psma-targeting compounds and uses thereof
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
US9371360B2 (en) * 2011-11-30 2016-06-21 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof
ES2648096T3 (es) * 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
SG11201602249RA (en) * 2013-10-18 2016-05-30 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN106660943B (zh) * 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
ES2912753T3 (es) 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
WO2016065435A2 (en) * 2014-10-30 2016-05-06 Katholieke Universiteit Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Also Published As

Publication number Publication date
SA518400103B1 (ar) 2022-03-20
PH12018502048A1 (en) 2019-07-01
ES2877572T3 (es) 2021-11-17
HUE065327T2 (hu) 2024-05-28
FI3925952T3 (fi) 2024-02-13
KR20230147751A (ko) 2023-10-23
RU2021115958A (ru) 2021-07-12
TR201813644T1 (tr) 2018-11-21
EP3433238A4 (en) 2019-09-11
ZA201806389B (en) 2024-01-31
KR20220063298A (ko) 2022-05-17
HRP20240215T1 (hr) 2024-04-26
NZ786380A (en) 2025-05-02
WO2017165473A1 (en) 2017-09-28
US20250195700A1 (en) 2025-06-19
JP2024050608A (ja) 2024-04-10
BR112018069507A2 (pt) 2019-01-29
EP3433238B1 (en) 2021-06-16
KR20180134918A (ko) 2018-12-19
PL3925952T3 (pl) 2024-04-22
AU2017238181B2 (en) 2021-05-27
RU2018133693A (ru) 2020-04-22
CY1124487T1 (el) 2022-07-22
SI3925952T1 (sl) 2024-03-29
RS62274B1 (sr) 2021-09-30
RU2018133693A3 (enExample) 2020-04-22
MX2018011519A (es) 2019-01-28
US20200155713A1 (en) 2020-05-21
JP2019519467A (ja) 2019-07-11
LT3925952T (lt) 2024-01-25
CN109311827B (zh) 2022-04-12
US11458213B2 (en) 2022-10-04
US20230015736A1 (en) 2023-01-19
NZ746701A (en) 2024-12-20
CL2018002683A1 (es) 2019-04-22
RU2749399C2 (ru) 2021-06-09
DK3925952T3 (da) 2024-02-05
AU2017238181A1 (en) 2018-10-18
MX384823B (es) 2025-03-14
EP3925952A1 (en) 2021-12-22
RS65188B1 (sr) 2024-03-29
CN109311827A (zh) 2019-02-05
DK3433238T3 (da) 2021-09-06
JP7073270B2 (ja) 2022-05-23
ES2972148T3 (es) 2024-06-11
JP2022116028A (ja) 2022-08-09
EP3433238A1 (en) 2019-01-30
CN114716387A (zh) 2022-07-08
KR20250057132A (ko) 2025-04-28
EP4385981A1 (en) 2024-06-19
PT3433238T (pt) 2021-07-28
HUE055607T2 (hu) 2021-12-28
EP3925952B1 (en) 2023-11-29
PL3433238T3 (pl) 2021-12-13
CN114716387B (zh) 2025-04-01
PT3925952T (pt) 2023-12-13
SI3433238T1 (sl) 2021-11-30
CA3018709A1 (en) 2017-09-28
LT3433238T (lt) 2021-09-27
HRP20211386T1 (hr) 2021-12-10
KR102396307B1 (ko) 2022-05-09

Similar Documents

Publication Publication Date Title
CN114716387B (zh) 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN111032632B (zh) 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
US20240140971A1 (en) Psma targeted radiohalogenated ureas for cancer radiotherapy
JP7503495B2 (ja) がん放射線治療法のための、ｐｓｍａをターゲットとした放射性ハロゲン化した尿素‐ポリアミノカルボン酸塩
KR102531494B1 (ko) 탄산 탈수효소 ix를 표적으로 하는 핵 영상화 및 방사선치료 제제 및 이의 용도
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂
BR122025009780A2 (pt) Compostos, método para tratar uma ou mais células ou tumores que expressam psma in vitro ou ex vivo que utiliza os ditos compostos e uso dos mesmos para tratar tumores ou células que expressam psma
CN119136846A (zh) Ntsr1靶向放射性药物及dna损伤反应抑制剂的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination